Heterocyclic compounds as 5HT2a biased agonists

Heterocyclic small-molecule compounds targeting the 5HT2A receptor as Gq-biased agonists address the inadequacies of current treatments by selectively activating Gq signaling, offering rapid relief for depression, anxiety, and substance abuse.

WO2026136510A1PCT designated stage Publication Date: 2026-06-25MT SINAI SCHOOL OF MEDICINE +3
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
MT SINAI SCHOOL OF MEDICINE
Filing Date
2025-12-17
Publication Date
2026-06-25

Smart Images

  • Figure US2025060065_25062026_PF_FP_ABST
    Figure US2025060065_25062026_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are compounds that are 5HT2A Gq-biased agonists and methods for use of such compounds in 5HT2A mediated diseases.
Need to check novelty before this filing date? Find Prior Art